A new device for In Vivo measurement of nasal transepithelial potential difference in cystic fibrosis patients and normal subjects

European Respiratory Journal

Volumn 10, Issue 7, 1997, Pages 1631-1636

  Duperrex, O ^a   Berclaz, P Y ^a   Bertrand, D ^a   Lacroix, J S ^a   Pochon, N ^a   Belli, D ^a   Rochat, T ^a,b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Chloride; Cystic fibrosis; Epithelium; Nose; Potential difference; Sodium

Indexed keywords

AMILORIDE;

ADULT; ARTICLE; CELL MEMBRANE POTENTIAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELECTRODE; FACIAL BONE; GENE THERAPY; HUMAN; ION TRANSPORT; NOSE MUCOSA; PRIORITY JOURNAL;

ADULT; AMILORIDE; CASE-CONTROL STUDIES; CYSTIC FIBROSIS; ELECTRIC CONDUCTIVITY; ELECTRODES; ENDOSCOPY; EQUIPMENT DESIGN; FEMALE; HUMANS; ION TRANSPORT; MALE; NASAL MUCOSA; PERFUSION; TERBUTALINE; TURBINATES;

EID: 0030757486     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10071631     Document Type: Article

References (16)

1. Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981; 124: 484-490.
2. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981; 305: 1489-1495.
3. Alton EWFW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990; 3: 922-926.
4. Chinet TC. Use of in vivo nasal transepithelial potential difference to evaluate efficacy in CF gene therapy phase I trials. Eur Respir J 1994; 7: 1917-1920.
5. Middleton PG, Geddes DM, Alton EWFW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994; 7: 2050-2056.
6. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocol for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445-455.
7. Caplen NJ, Alton EWFW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1: 39-46.
8. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995; 6: 1487-1496.
9. Zabner J, Ramsey BW, Meeker DP, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.
10. Sturgess JM. Ciliated cells of the lung. In: Massaro D, ed. Lung Cell Biology. New York, Marcel Dekker Inc., 1989; pp. 115-151.
11. Knowles M, Gatzy J, Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest 1983; 71: 1410-1417.
12. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channel. Science 1995; 269: 847-850.
13. Egan M, Flotte T, Afione S, et al. Defective regulation of outwardly rectifying chloride channels by protein kinase A corrected by insertion of CFTR. Nature 1992; 358: 581-584.
14. Stewart B, Zabner J, Shuber AP, Welsh MJ, McCray PB. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 899-903.
15. Welch WJ, Brown CR, Brown LQ, et al. Chemical chaperones correct protein folding abnormalities. Pediatr Pulmonol 1996; Suppl. 13: 258.
16. Rubenstein RC, Brusilow SW, Hamosh A, Zeitlin PL. Clinical trials of 4-phenylbutyrate for correction of sweat duct abnormalities in ΔF508 homozygous cystic fibrosis patients. Pediatr Pulmonol 1996; Suppl. 13: 259.